Nektar Rezpegaldesleukin Phase 3: $2.3B T-Reg Bet

Nektar Therapeutics (NKTR) closed at $69.36 on July 23, 2026. That gives the company a $2.34 billion market cap on trailing twelve-month revenue of roughly $11 million. The price-to-sales ratio is 213x. Nektar has 63 employees and zero approved drugs. The market is pricing this company almost entirely on one molecule, and that molecule just moved from “interesting science” to “show me the money.”

On July 21, Nektar announced the initiation of two global registrational Phase 3 trials, ZENITH AD-1 and ZENITH AD-2, for rezpegaldesleukin in moderate-to-severe atopic dermatitis. A third trial, ZENITH AD-3, starts in September. FDA granted Fast Track designation. The first Phase 3 topline data is expected in 2027. This is the moment where Nektar either validates a novel immunological mechanism or becomes another cautionary tale in the biotech graveyard.

The mechanism: T-reg stimulation, not cytokine blocking

Every approved biologic for atopic dermatitis works by blocking something. Dupixent (dupilumab) blocks IL-4 and IL-13 signaling. JAK inhibitors like Rinvoq and Cibinqo block inflammatory kinase pathways downstream. The entire treatment model is suppression: find the inflammatory cytokine, shut it down, manage the side effects.

Rezpegaldesleukin does the opposite. It is a first-in-class regulatory T-cell (T-reg) stimulator, a modified form of interleukin-2 conjugated to a polymer that preferentially activates regulatory T-cells. T-regs are the immune system’s brakes. Instead of blocking specific inflammatory pathways one at a time, rezpegaldesleukin amplifies the cells that restore immune balance upstream. The theoretical advantage: broader immune modulation across multiple disease pathways, with the possibility of disease modification rather than symptom management.

This is not a me-too drug. If Phase 3 succeeds, rezpegaldesleukin would be the first T-reg biologic approved for any autoimmune disease. The mechanism is novel enough that the FDA granted Fast Track designation, and the European Medicines Agency provided scientific advice on the Phase 3 design.

Phase 2b: the data that earned the Phase 3 ticket

The Phase 2b REZOLVE-AD trial (NCT06136741) enrolled 393 patients with moderate-to-severe atopic dermatitis across approximately 110 sites globally. The primary endpoint was mean improvement in Eczema Area and Severity Index (EASI) at week 16. Every dose arm hit statistical significance on the primary endpoint.

The high dose, 24 ug/kg every two weeks, delivered the largest effects. Mean percent change in EASI was statistically significant at p<0.001 versus placebo. EASI-75 (75% improvement from baseline) was achieved at p<0.001. EASI-90 (90% improvement) hit p<0.05. vIGA-AD 0/1 (clear or almost clear skin) reached p<0.05. Itch NRS response (4-point or greater reduction in itch) was p<0.01. Every primary and secondary endpoint, met.

The crossover data is where it gets interesting. Forty-two placebo patients crossed over to receive high-dose rezpegaldesleukin after week 16. Among the 21 who reached 24 weeks of treatment, EASI-75 response deepened from 50% at crossover week 16 to 62% at crossover week 24. vIGA-AD 0/1 improved from 28% to 38%. Extended dosing produced deeper responses, which suggests the T-reg mechanism builds cumulative benefit rather than plateauing. That is unusual in dermatology biologics, and it is the data point most likely to differentiate rezpegaldesleukin from the competition in Phase 3.

There was also an unexpected finding in a comorbid asthma subgroup. Among 99 patients with a history of asthma, all three rezpegaldesleukin doses reduced mean ACQ-5 scores (asthma control questionnaire) at week 16 versus placebo. In the 25 patients with uncontrolled asthma at baseline, 75% of those on the high dose achieved a clinically significant improvement. This is a signal that T-reg stimulation may work across multiple inflammatory conditions simultaneously, which has obvious implications for the broader pipeline.

The competition: Dupixent’s shadow

Atopic dermatitis is a $16.4 billion market in 2026, and Dupixent is the gravity well at its center. Sanofi reported Dupixent sales of EUR 4.17 billion in Q1 2026 alone, up 30.8% year over year. Sanofi projects EUR 22 billion in Dupixent sales by 2030. Over one million patients are treated with Dupixent globally. It is the dominant biologic in the space, and it has six approved indications including asthma, COPD, and eosinophilic esophagitis.

JAK inhibitors are gaining share behind Dupixent. Rinvoq (AbbVie) and Cibinqo (Pfizer) offer oral dosing convenience, though both carry black box warnings for cardiovascular events and malignancy that have limited their uptake in earlier treatment lines. Rezpegaldesleukin would enter as a fourth mechanism: an injected biologic that does not block cytokines but rather restores the immune system’s own regulatory function.

The commercial question is whether a novel mechanism with a strong safety profile (no treatment-related severe adverse events in Phase 2b) can win share from a entrenched incumbent with 10 years of real-world safety data. In atopic dermatitis specifically, the answer may be yes: roughly 40-50% of Dupixent patients do not achieve adequate response, and the JAK inhibitor safety warnings have created room for a new biologic. But winning even 5% of a $16 billion market means $800 million in peak sales potential, and that is the bull case.

Nektar is also developing rezpegaldesleukin in alopecia areata, with a Phase 2b study showing 30% mean reduction in SALT scores at 36 weeks (p<0.05 versus placebo). A Phase 3 in alopecia areata is planned for early 2027. The addressable market in severe alopecia areata is smaller than atopic dermatitis but largely untreated: the only approved drug is Lilly’s Olumiant, which has modest efficacy. For more on how FDA approval decisions in dermatology play out, see our coverage of GSK’s Jideytro approval and the broader framework for reading clinical trial readouts in our guide to interpreting clinical trial data.

Valuation: pricing in perfection at $2.3B

Nektar’s $2.34 billion market cap sits in an awkward zone. The company is not cheap enough to be a lottery ticket, and it is not expensive enough to suggest the market has fully priced in commercial success.

Canaccord Genuity initiated coverage on July 22 with a Buy rating and a $153 price target, implying 122% upside from the current $69.36. The average analyst price target is $156.32, ranging from a low of $80 (Wedbush, Neutral) to a high of $192. The Canaccord target implies a roughly $5.2 billion market cap at the midpoint, which would require rezpegaldesleukin to reach peak sales of $1-2 billion across atopic dermatitis and alopecia areata combined. At a 3-4x peak sales multiple, that math works if Phase 3 succeeds.

Compare Nektar’s valuation to Regenabio or Arena Pharmaceuticals before its Pfizer acquisition: clinical-stage immunology companies with novel mechanisms trade at 2-4x peak sales estimates once Phase 3 is underway. Nektar’s $2.3B market cap implies roughly $600-800 million in peak sales expectations at a 3x multiple, which is conservative if the T-reg platform works in multiple indications. But if Phase 3 fails, Nektar has limited pipeline depth beyond rezpegaldesleukin. The company also has NKTR-255 (an IL-15 agent in oncology) and two preclinical assets (NKTR-0165, NKTR-0166), but none are near the clinic in a meaningful way.

The burn rate matters. Nektar’s Q1 2026 revenue was $10.9 million, almost entirely from collaboration and royalty income. The company will need substantial capital to run three Phase 3 trials plus a Phase 3 in alopecia areata. A secondary offering between now and 2027 topline data is a real risk, and dilution at $69 per share would hurt existing shareholders significantly. For context on how post-approval commercial realities can diverge from clinical promise, see our analysis of Celcuity gedatolisib Revtorpyk’s post-approval 18% decline.

Risk: the T-reg mechanism is unproven in Phase 3

Every novel mechanism that works in Phase 2 has a graveyard of Phase 3 failures behind it. T-reg stimulation has never succeeded in a Phase 3 trial for any autoimmune disease. The Phase 2b results were strong, but the trial was 393 patients. Phase 3 will enroll thousands across three trials. The placebo response in atopic dermatitis trials is notoriously variable, and a 35% placebo response rate (observed in REZOLVE-AD) can swing a trial outcome if it rises to 40-45% in a larger population.

The specific risk factors are: (1) Phase 3 trials in atopic dermatitis have historically had a 30-40% failure rate for novel mechanisms, (2) the 24-week induction design means the primary endpoint is at 24 weeks, not 16, and longer trials increase the chance of placebo normalization or safety signals emerging, (3) the T-reg mechanism depends on adequate T-reg cell numbers in each patient, which may vary across populations and geographies, and (4) Dupixent is expanding into earlier treatment lines and pediatric populations, which could shrink the treatment-naive population that ZENITH AD-1 and AD-2 are enrolling before rezpegaldesleukin reaches market.

Verdict

I am cautiously bullish on Nektar at $69.36, but the word “cautiously” is doing heavy lifting. The Phase 2b data was genuinely strong across every endpoint with consistent p-values, the crossover deepening data is unusual and encouraging, and the T-reg mechanism is differentiated enough from Dupixent and JAK inhibitors to carve out a niche in a $16 billion market. The Fast Track designation and Phase 3 initiation de-risk the regulatory pathway.

The problem is that the stock already reflects meaningful Phase 3 expectations. At $2.3 billion market cap with $11 million in revenue and a single lead asset entering registrational trials, the downside to a Phase 3 failure is 60-70% and the upside to success is 100-120% per the analyst consensus. This is a binary bet on a novel mechanism that has never been validated in Phase 3. The risk-reward is favorable if you believe the Phase 2b data, and the data is the best you could ask for at this stage.

My target: $120 per share by mid-2027 if ZENITH AD interim data confirms the Phase 2b response rates, with a floor of $35-40 if the primary endpoint misses. The expected value math, weighting 55% success probability based on the strength of the Phase 2b data, gives a fair value around $78 today. The stock is fairly valued, not cheap. I would not chase it here, but I would buy aggressively on any pullback below $55 where the risk-reward tilts clearly favorable. The T-reg platform is real science. The stock is not a bargain.

---

Sources: ClinicalTrials.gov NCT06136741, Nektar Phase 3 press release, Nektar REZOLVE-AD Phase 2b data, Polygon API (NKTR price data), Finnhub API.